替罗非班联合阿替普酶对急性ST段抬高心肌梗死患者经皮冠脉支架置入术中心肌组织灌注的比较研究  

Comparative Study of Tirofiban Plus Alteplase on Myocardial Tissue Perfusion during Percutaneous Coronary Stenting for Acute ST-segment Elevation Myocardial Infarction Patients

作　　者：刘永枝 彭永校 LIU Yong-zhi;PENG Yong-xiao(Department of Internal Medicine,Jiexi People's Hospital,Jieyang,Guangdong Province,515400 China)

机构地区：[1]广东省揭阳市揭西县人民医院内二区,广东揭阳515400

出　　处：《中外医疗》2020年第6期103-105,共3页China & Foreign Medical Treatment

摘　　要：目的比较替罗非班联合阿替普酶对急性ST段抬高心肌梗死(STEMI)患者经皮冠脉支架置入术中心肌组织灌注效果。方法方便选取该院2018年9月-2019年8月收治的60例行经皮冠脉支架置入术的STEMI患者展开对照研究,将其分为观察组(替罗非班联合阿替普酶治疗)与对照组(替罗非班治疗)各30例,分组方为随机数字表法,探讨实施不同治疗对治疗效果的影响。结果观察组患者心肌组织再灌注分级情况明显好于对照组(χ~2=8.603,P<0.05),研究对象在总有效率上相比,观察组(96.67%)显著比对照组(76.67%)高(χ~2=5.192,P<0.05)。结论将替罗非班联合阿替普酶应用于STEMI患者经皮冠脉支架置入术时,可显著提升疗效,改善患者心肌组织再灌注状况,此方法值得应用与推广。Objective To compare the effects of tirofiban plus alteplase on myocardial tissue perfusion during percutaneous coronary stenting for acute ST-segment elevation myocardial infarction(STEMI) patients. Methods 60 STEMI patients underwent percutaneous coronary stenting from September 2018 to August 2019 in the hospital were convenient selected.According to random number table, patients were assigned to observation group(n =30) and control group(n =30). The observation group was treated with tirofiban and alteplase;the control group was treated with alteplase. The therapeutic effect was discussed. Results The myocardial tissue perfusion grading in the observation group was significantly better than control group(χ~2=8.603, P<0.05);the total effective rate in the observation group(96.67%) was significantly higher than control group(76.67%)(χ~2=5.192, P<0.05). Conclusion The combination of tirofiban and alteplase can remarkably improve the clinical efficacy and myocardial tissue perfusion conditions. It is worthy of clinical application and promotion.

关 键 词：阿替普酶 替罗非班 经皮冠脉支架置入术 急性ST段抬高心肌梗死 

分 类 号：R542.2[医药卫生—心血管疾病]